(CercleFinance.com) – Carmat announced last night that it ended 2021 with cash of 39.2 million euros, which gives the artificial heart manufacturer financial visibility until July 2022.
In 2021, its turnover amounted to 2.2 million euros, corresponding to the sale of 10 Aeson systems, including seven commercially, in Germany and Italy, and three as part of a study in the USA.
The operating loss amounted to 60.4 million euros, i.e. a deterioration of 24 million euros compared to the previous financial year, in particular due to the recognition of a non-recurring charge of 8.1 million euros. euros related to quality problems that impacted some of its prostheses.
In its press release, Carmat says it is “actively” exploring different options in order to secure the funding necessary to continue its activities beyond July 2022.
Invest Securities analysts this morning evoke a “limited” financial visibility, which did not prevent the title from gaining nearly 2.5% on Wednesday morning on the Paris Stock Exchange.
The action still shows a fall of almost 38% since the beginning of the year.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
